A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Hair thinning in men is a prevalent issue for which treatment oftentimes consists of a multi-modal approach.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, men only.

Men aged 21-61 years old with confirmed hair thinning were included.

Subjects were randomized to receive the oral supplement or placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

This was a 6-month multi-center, double-blind, randomized, placebo-controlled trial.

The study end points included changes in blinded Global Investigator Ratings for hair growth and quality, the Men's Hair Growth Questionnaire (MHGQ), and changes in the Arizona Sexual Experience Scale (ASEX) in the active group compared to baseline and placebo.

What Was Measured

Topics PubMed links to this paper include Alopecia, Dietary Supplements, Hair, Plant Extracts and Surveys and Questionnaires.

The authors tagged it with the keywords MPHL, botanicals, hair thinning, male pattern hair loss and nutraceutical.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of cosmetic dermatology), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.